secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001140361-26-011991
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio submits NDA to FDA for BBP-418 for LGMD2I/R9; potential first approved therapy
--------------------------------------------------------------------------------

- NDA submission for oral BBP-418 in limb-girdle muscular dystrophy type 2I/R9.
- Phase 3 FORTIFY interim analysis met all primary and secondary endpoints at 12 months.
- FDA approval and U.S. launch anticipated in late 2026 / early 2027.
- BBP-418 has Orphan Drug, Fast Track, and Rare Pediatric Disease designations from FDA.
- Company also engaging European regulators for expedited approval path.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126011991/0001140361-26-011991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126011991/ef20069329_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-011991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer